Clinical trials in desmoid-type fibromatosis in children and adults: A systematic review.
Simone A van MarenMax M van NoeselOlga HussonWinette T A van der GraafPublished in: Pediatric blood & cancer (2022)
Desmoid-type fibromatosis (DTF) is a rare locally aggressive soft tissue neoplasm, which occurs in children and adults, with a peak incidence in young adults. For the majority of the patients, DTF is a chronic and symptomatic disease, which affects health-related quality of life. Systemic treatment regimens tend to differ for patients treated by pediatric oncologists compared to medical oncologists. This systematic review identified 14 clinical trials in children and adults with DTF. Tumor response and progression-free survival rates varied widely between studies and study populations. Treatment choices for patients with DTF are based on a paucity of (randomized) trials. Treatment principles of DTF are similar in pediatric and adult oncology, but the treatment itself is different. This seems mostly driven by a lack of tyrosine kinase inhibitor (TKI) accessibility in pediatric oncology. An insufficient number of studies examined patient-reported outcomes, which are extremely important for patients with a chronic disease like DTF.
Keyphrases
- young adults
- clinical trial
- systematic review
- patient reported outcomes
- healthcare
- randomized controlled trial
- palliative care
- soft tissue
- free survival
- combination therapy
- risk factors
- end stage renal disease
- tyrosine kinase
- replacement therapy
- advanced cancer
- smoking cessation
- chronic myeloid leukemia
- genetic diversity
- high grade
- advanced non small cell lung cancer